Figure S1. A, Representative fluorescence micrographs show AD-VEGF-C-EGFP expression in distal colon (right panel) and proximal colon (left panel). B, High expression of recombinant adenovirus AD-VEGF-C in 293 cells detected by real time qPCR. Data are reported as mean±SD (n=5/per group). AD-VEGF-C: adenovirus vascular endothelial growth factor-C.
Figure S2. Representative fluorescence micrographs of dendritic cells in DSS-induced acute colitis. There was a significantly higher number of CD11c-positive dendritic cells in the AD-VEGF-C-treated mice (A - a, b, B; P=0.004) and recombinant VEGF-C156S-treated mice (A - c, d, C; P=0.002), compared to DSS-treated and PBS-treated mice, respectively. Data are reported as means±SD. *P<0.05 compared to DSS- or PBS-treated mice (n=5/group). †P<0.05 compared to water-treated mice (n=5/group). Statistical analysis was performed by ANOVA and Bonferroni's post-hoc test. AD-VEGF-C: adenovirus vascular endothelial growth factor-C; DSS: dextran sodium sulfate.
Figure S3. Representative fluorescence micrographs of neutrophils in DSS-induced acute colitis (A). Comparison of myeloperoxidase (MPO)-positive neutrophils between AD-VEGF-C-treated and DSS-treated mice (B) and between recombinant VEGF-C156S-treated and PBS-treated mice (C). There was no significant difference in the number of MPO-positive neutrophils in the colonic mucosa between the AD-VEGF-C-treated and control mice (P>0.05). However, VEGF-C156S-treated mice had a significantly higher number of MPO-positive neutrophils compared to PBS-treated mice (P=0.018). Data are reported as means±SD. *P<0.05 compared to DSS- or PBS-treated mice (n=5/group). †P<0.05 compared to water-treated mice (n=5/group). Statistical analysis was performed by ANOVA and Bonferroni's post-hoc test. AD-VEGF-C: adenovirus vascular endothelial growth factor-C; DSS: dextran sodium sulfate.
Figure S4. Comparison of colon thickness between AD-VEGF-C-treated and DSS-treated mice (A) and between AD-VEGF-C156S-treated and PBS-treated mice (B). Colon thickness was significantly increased in VEGF-C-treated and VEGF-C156S-treated mice compared to DSS- and PBS-treated mice, respectively (both P<0.001). Data are reported as means±SD (n=5/group). *P<0.05 compared to DSS- or PBS-treated mice. †P<0.05 compared to water-treated mice. Statistical analysis was performed by ANOVA and Bonferroni's post-hoc test. AD-VEGF-C: adenovirus vascular endothelial growth factor-C; DSS: dextran sodium sulfate.